TY - JOUR
T1 - Quantification of hepatitis B virus (HBV) DNA with a TaqMan HBV analyte-specific reagent following sample processing with the MagNA pure LC instrument
AU - Germer, Jeffrey J.
AU - Qutub, Mohammed O.
AU - Mandrekar, Jayawant N.
AU - Mitchell, P. Shawn
AU - Yao, Joseph D.C.
PY - 2006/4
Y1 - 2006/4
N2 - TaqMan hepatitis B virus (HBV) analyte-speciflc reagent (ASR; Roche Molecular Systems, Inc., Branchburg, NJ) is designed for the quantification of HBV DNA in serum or plasma. The performance characteristics of TaqMan HBV ASR following automated sample processing with the MagNA Pure LC instrument (MP; Roche Applied Science, Indianapolis, IN) were evaluated in this study. Analytical sensitivity and precision were assessed with commercially available HBV standards, while clinical serum specimens from HBsAg-seropositive patients and healthy blood donors were used to determine clinical sensitivity, specificity, and correlation with other commercially available assays. Analytical studies yielded a limit of detection of 2.4 IU/ml, with good linearity and correlation (R2 = 0.9958) with expected HBV DNA titers over a wide range (6.0 × 100 to 2.1 × 108 IU/ml). Clinical sensitivity and specificity of the assay combined with automated sample processing were both 100%. Comparison of TaqMan HBV ASR and VERSANT HBV DNA 3.0 assay (bDNA; Bayer HealthCare LLC, Tarrytown, NY) results among clinical specimens yielded good correlation (R2 = 0.9237), with a mean difference in titer of -0.213 log10 IU/ml (95% confidence interval, -0.678 to 1.10 log10 IU/ml). The overall test failure rate was 2.0% among 204 clinical serum specimens tested. Total time required for MP sample processing and automated postelution handling of 24 samples was 224 min, with 57 min of actual hands-on time. MP is a reliable, labor-saving platform suitable for use with TaqMan HBV ASR, providing sensitive and accurate quantification of HBV DNA levels over a range of 8 log10 IU/ml.
AB - TaqMan hepatitis B virus (HBV) analyte-speciflc reagent (ASR; Roche Molecular Systems, Inc., Branchburg, NJ) is designed for the quantification of HBV DNA in serum or plasma. The performance characteristics of TaqMan HBV ASR following automated sample processing with the MagNA Pure LC instrument (MP; Roche Applied Science, Indianapolis, IN) were evaluated in this study. Analytical sensitivity and precision were assessed with commercially available HBV standards, while clinical serum specimens from HBsAg-seropositive patients and healthy blood donors were used to determine clinical sensitivity, specificity, and correlation with other commercially available assays. Analytical studies yielded a limit of detection of 2.4 IU/ml, with good linearity and correlation (R2 = 0.9958) with expected HBV DNA titers over a wide range (6.0 × 100 to 2.1 × 108 IU/ml). Clinical sensitivity and specificity of the assay combined with automated sample processing were both 100%. Comparison of TaqMan HBV ASR and VERSANT HBV DNA 3.0 assay (bDNA; Bayer HealthCare LLC, Tarrytown, NY) results among clinical specimens yielded good correlation (R2 = 0.9237), with a mean difference in titer of -0.213 log10 IU/ml (95% confidence interval, -0.678 to 1.10 log10 IU/ml). The overall test failure rate was 2.0% among 204 clinical serum specimens tested. Total time required for MP sample processing and automated postelution handling of 24 samples was 224 min, with 57 min of actual hands-on time. MP is a reliable, labor-saving platform suitable for use with TaqMan HBV ASR, providing sensitive and accurate quantification of HBV DNA levels over a range of 8 log10 IU/ml.
UR - http://www.scopus.com/inward/record.url?scp=33645921308&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33645921308&partnerID=8YFLogxK
U2 - 10.1128/JCM.44.4.1490-1494.2006
DO - 10.1128/JCM.44.4.1490-1494.2006
M3 - Article
C2 - 16597881
AN - SCOPUS:33645921308
SN - 0095-1137
VL - 44
SP - 1490
EP - 1494
JO - Journal of clinical microbiology
JF - Journal of clinical microbiology
IS - 4
ER -